Autoimmune DiseasesNCT04838171
Prospective Study of White Blood Cells
An observational study of Autoimmune Diseases and Inflammation, run by Quell Therapeutics Limited at 1 site in United Kingdom.
Trial summary
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- What is being tested?
- White blood cell and blood collection
- How many people
- 10 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 24 Mar 2021to Jan 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Volunteers willing to provide white blood cells for research.
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Quell Investigator Site 01
London
About this study
Official title: Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Being tested
- White blood cell and blood collection
- Medical subject headings
- Autoimmune Diseases, Inflammation, Rejection, Psychology
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
White blood cell and blood collectionOther
Mononucleocytes will be collected via apheresis
| Study group | Role | What they receive |
|---|---|---|
| Specimen collection to support development of engineering Treg | Not described Receives: Other: White blood cell and blood collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
WBC characterisation to support the development of engineered regulatory T cells.
number, type and function of white blood cells in healthy controls and in patients
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2021
- Study start24 Mar 2021
- Primary completion31 Dec 2029 (estimated)
- Study completionJan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autoimmune DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Quell Therapeutics Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04838171
- Sponsor's protocol ID
- QEL-RP-001
- Status last verified
- Jan 2026
- First submitted
- 1 Apr 2021
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
- ClinicalTrials.gov ID
- NCT04838171
- Acronym / sponsor ID
- QEL-RP-001
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Quell Therapeutics LimitedIndustry (pharma, biotech, devices)
- Study start
- 24 Mar 2021 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- Jan 2030 (estimated)
- First posted
- 8 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Specimen collection to support development of engineering Treg | – | Other: White blood cell and blood collection |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Volunteers willing to provide white blood cells for research.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| White blood cell and blood collectionMononucleocytes will be collected via apheresis | Other | Specimen collection to support development of engineering Treg |
Primary outcome
WBC characterisation to support the development of engineered regulatory T cells.
Time frame: 5 years
number, type and function of white blood cells in healthy controls and in patients
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Autoimmune Diseases
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autoimmune Diseases and Inflammation, run by Quell Therapeutics Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gareth Wright (+4(0)2070969012, contact@quell-tx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
WBC characterisation to support the development of engineered regulatory T cells. (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.